ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Heart Failure Pregnancy: Avoid — not systemically absorbed but insufficient safety data; seek specialist advice

Patiromer

Brand names: Veltassa

Adult dose

Dose: 8.4 g once daily starting dose; titrate to 16.8 g or 25.2 g once daily based on serum potassium
Route: Oral
Frequency: Once daily with food
Max: 25.2 g once daily
Mix powder in 40 mL water; stir well and drink immediately; then rinse with additional water and drink. Take with food. Separate from other oral medications by at least 3 hours (adsorption interaction).

Paediatric dose

Dose: Seek specialist opinion N/A/kg
Route: Oral
Frequency: N/A
Max: N/A
Not established in paediatrics; seek specialist nephrology opinion

Dose adjustments

Renal

No dose adjustment — patiromer is not absorbed systemically; particularly useful in CKD patients on RAAS therapy with hyperkalaemia

Hepatic

No dose adjustment — not systemically absorbed

Paediatric weight-based calculator

Not established in paediatrics; seek specialist nephrology opinion

Clinical pearls

  • Mechanism: non-absorbed cation exchange polymer — patiromer is a calcium-sorbitol polymer that exchanges calcium for potassium in the colon; binds approximately 4.5 mmol K+ per gram; unlike sodium polystyrene sulfonate, patiromer does not cause sodium retention
  • DIAMOND trial (NEJM 2019): patiromer in HFrEF patients with hyperkalaemia on RAAS inhibitor — patiromer enabled significantly more patients to remain on spironolactone/eplerenone at full dose; spironolactone withdrawal increased HF events; patiromer resolved hyperkalaemia and allowed RAAS therapy continuation
  • Clinical niche: KEY role is enabling RAAS inhibitor continuation (ACE inhibitor, ARB, MRA) in HF and CKD patients who develop hyperkalaemia — rather than stopping life-saving medications
  • MHRA 2017: licensed for treatment of hyperkalaemia in adults; NICE TA592: recommended for hyperkalaemia associated with RAASi therapy in patients with CKD or HF
  • Hypomagnesaemia: check serum magnesium at baseline and periodically — supplement if below 0.7 mmol/L; patiromer also binds Mg2+ ions in the colon
  • Not for acute hyperkalaemia: onset of action 7–24 hours — use IV calcium, insulin/dextrose, or salbutamol for acute treatment; patiromer is a chronic maintenance agent

Contraindications

  • Severe or life-threatening hyperkalaemia (requires urgent IV treatment first — patiromer is not rapid-acting)
  • Bowel obstruction (relative)

Side effects

  • Hypomagnesaemia (most common — patiromer also binds magnesium in gut)
  • Constipation
  • Diarrhoea
  • Abdominal discomfort
  • Hypokalaemia (with excessive use)

Interactions

  • ALL oral medications — patiromer binds many drugs in gut; take all other medications at least 3 hours apart
  • ACE inhibitors and ARBs (patiromer enables continued use by treating hyperkalaemia — this is the intended benefit)
  • Thyroid hormones, fluoroquinolones, metformin (significant binding — separate by 3 hours or more)

Monitoring

  • Serum potassium at 1 week, then monthly until stable
  • Serum magnesium (baseline and periodically — hypomagnesaemia risk)
  • Renal function and eGFR
  • Other electrolytes

Reference: BNFc; BNF 90; DIAMOND trial NEJM 2019;380(18):1717-1728; NICE TA592; MHRA 2017; ESC HF Guidelines 2021. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways